title: Intravesical suramin in the prevention of transitional cell carcinoma.
abstract: OBJECTIVE
  To examine the effects of intravesical suramin on N-methyl-N-nitrosurea (MNU)-induced bladder tumors in Fischer 344 rats.
  
  
  METHODS
  Multiple cohorts of female rats received four biweekly intravesical instillations of MNU. A control group received no other treatment, the experimental group received 25 mg/kg intravesical suramin twice a week beginning at week 6.
  
  
  RESULTS
  After 18 weeks from the first instillation of MNU, 60% to 65% of control animals developed papillary transitional cell carcinoma, compared with only 0% to 10% of the suramin-treated animals (P = 0.01 to P = 0.0007). There was no local or systemic toxicity observed.
  
  
  CONCLUSIONS
  Intravesical suramin is an effective chemopreventative therapy for transitional cell carcinoma in vivo with minimal toxicity.
authors: Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.
authors: S D
authors: SD
authors: Graham
authors: P
authors: P
authors: Napalkov
authors: A
authors: A
authors: Oladele
authors: T E
authors: TE
authors: Keane
authors: J A
authors: JA
authors: Petros
authors: H S
authors: HS
authors: Clarke
authors: V S
authors: VS
authors: Kassabian
authors: D L
authors: DL
authors: Dillehay
mesh_terms: D000283:Administration, Intravesical; D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control*; D005260:Female; D008770:Methylnitrosourea; D051381:Rats; D011916:Rats, Inbred F344; D013498:Suramin / Q000008:administration & dosage* / Q000097:blood / Q000633:toxicity; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D013498:Suramin; D008770:Methylnitrosourea